Unveiling the Side Effects of Anti-Obesity Drugs
New anti-obesity drugs such as semaglutide and tirzepatide have shown promising results in clinical trials, leading to substantial weight loss and reduced cardiovascular risk. However, researchers are now investigating potential side effects, including gastrointestinal problems and loss of muscle mass. A recent study found that semaglutide was associated with a higher incidence of pancreatitis and gastroparesis compared to other weight-loss medications. Concerns about muscle-mass loss have prompted pharmaceutical companies to develop drugs that preserve muscle mass during weight loss. Specialists emphasize the importance of educating patients and providers about the risks and benefits of these medications, while acknowledging the need for further research in real-world conditions.